A Phase II Trial of High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy (SABR) for Patients With Metastatic Clear Cell Renal Cell Cancer (mRCC)
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 11 Mar 2019
Price : $35 *
At a glance
- Drugs Aldesleukin (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 01 Mar 2018 Planned End Date changed from 1 Dec 2017 to 1 Dec 2019.
- 01 Mar 2018 Status changed from recruiting to active, no longer recruiting.